Secondary analysis of two placebo-controlled RCTs (27,347 postmenopausal women): CHD risk with CEE+MPA was more than doubled in untreated women with LDL ≥190 mg/dL (HR 2.77) but not raised with normal LDL or treated hyperlipidaemia.
Secondary analysisn = 27,347 women
Rossouw et al. Influence of Cardiometabolic Status on Cardiovascular Effects of Oral Menopausal Hormone Therapy